Business Wire

Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients

SCHLIEREN/ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a biotech company developing best-in-class therapeutic antibodies, announced today that the U.S. Food and Drug ...
Healio

FDA grants Memo Therapeutics fast track designation to treat transplant-related infection

Please provide your email address to receive an email when new articles are posted on . FDA granted fast track designation for AntiBKV. AntiBKV is designed to treat BK polyomavirus infections in ...
Business Insider

Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union

Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare ...
manilatimes

Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union

Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare diseases Recognizes both medical plausibility of the initial clinical data and ...